Companies

JOHNSON & JOHNSON

JNJ · CIK 0000200406 · operating

$248.43+2.04%Last updated Feb 27, 10:04 PM

Key Statistics

Valuation

Market Cap$598.69B
P/E22.52
Fwd P/E19.80
PEG
P/S6.36
P/B7.34
EV/EBITDA18.56
EV/Rev6.67

Profitability

Gross Margin67.88%
Op. Margin
Net Margin28.46%
ROE
ROA13.46%
FCF Margin20.91%

Financial Health

Current Ratio1.03
Debt/Equity
Free Cash Flow$19.70B
Div. Yield2.09%

Growth & Other

Revenue Growth6.05%
EPS Growth90.50%
Beta0.35
52W High$248.94
52W Low$141.5

About JOHNSON & JOHNSON

Founded in 1886, Johnson & Johnson is a diversified healthcare company engaged in the research, development, manufacture, and distribution of pharmaceuticals and medical devices across more than 60 countries. The company operates through two primary segments: Innovative Medicine, which develops and markets prescription pharmaceutical products, and MedTech, which produces medical devices and related technologies.

The Innovative Medicine segment focuses on therapeutic areas including oncology, immunology, neuroscience, cardiovascular disease, infectious diseases, and pulmonary hypertension. Products are distributed through wholesalers, retailers, hospitals, and healthcare professionals. The MedTech segment manufactures surgical instruments, orthopedic devices, cardiovascular products, and vision care solutions. Notable product lines include ACUVUE contact lenses, TECNIS intraocular lenses, and a range of surgical instrumentation, energy devices, and wound closure systems used in open, laparoscopic, and robotic surgical procedures.

Johnson & Johnson operates at significant scale with approximately 138,200 full-time employees and maintains a presence across multiple distribution channels including hospitals, clinics, wholesalers, and retailers. The company maintains headquarters in New Brunswick, New Jersey, and is incorporated in the state of New Jersey.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2025$11.03$11.13+90.5%
2024$5.79$5.84+246.7%
2023$1.67$1.68-75.2%
2022$6.73$6.83-13.8%
2021$7.81$7.93+41.7%
2020$5.51$5.59+267.3%
2019$1.50$1.52+33.9%
2018$1.12$1.14+128.1%
2017$-3.99$-3.99-389.1%
2016$1.38$1.41+20.0%
2015$1.15$1.16+29.2%
2014$0.89$0.90-27.6%
2013$1.23$1.25+35.2%
2012$0.91$0.93+1037.5%
2011$0.08$0.08-88.6%
2010$0.70$0.71-84.1%
2009$4.40$4.45

Annual Reports (10-K) · 9 filings

Report DateFiledAccession Number
2025-12-282026-02-110000200406-26-000016SEC ↗
2024-12-292025-02-130000200406-25-000038SEC ↗
2023-12-312024-02-160000200406-24-000013SEC ↗
2023-01-012023-02-160000200406-23-000016SEC ↗
2022-01-022022-02-170000200406-22-000022SEC ↗
2021-01-032021-02-220000200406-21-000008SEC ↗
2019-12-292020-02-180000200406-20-000010SEC ↗
2018-12-302019-02-200000200406-19-000009SEC ↗
2017-12-312018-02-210000200406-18-000005SEC ↗